Algenex’ core expertise is in the production of subunit vaccines using Baculovirus vectors.

Algenex develops innovative biotechnology products to boost and simplify the development of veterinary and human vaccines.

Algenex’s patented technologies ease the production of recombined proteins leveraging insects cells as natural single-use bioreactors for protein expression. Insects larvae suchs as Trichoplusia ni can host the very same Baculoviridiae vectors employed in conventional production of many vaccines to obtain Virus-like particles (VLPs)

Insect-cell based Baculovirus expression systems allow vector testing and going to mass production of subunit vaccines economically and rapidly than state-of-the-art bioreactor-based technologies.

This versatile and robust biotechnology offers additional benefits such as linear scalability once the production parameters have been defined, significantly reduced production costs, and increased productivity, reaching up to gram per liter yields. As a result, Algenex is positioned to produce and deploy in the short term large quantities of recombinant putified proteins to pharmaceutical companies, so they are able to develop and manufacture vaccines quickly and at competitive prices.

To date, Algenex’ has developed more than 200 molecules successfully produced in collaboration with public and private partners, including international pharmaceutical companies.

CrisBio® harnesses pupae from the Trichoplusia ni as living bioreactors to take recombinant protein production to the next level.

Pupae are "programmed" to produce recombinant proteins by inoculation with a virus containing Algenex' improved expression cassette TopBac®.

CrisBio® and Topbac® are propietary, patent protected technologies which can be applied in combination or on a stand-alone basis.

CrisBio®

CrisBio®

Current production methods for recombinant proteins present a series of challenges in respect to development speed, scalability, technical complexity and cost.

CrisBio®, is an automated process that enables productivity of gram/litre levels with an extremely low investment and the upside of production flexibility and immediate scalability.

CrisBio® is a simple and robust process that has proven efficient in producing complex antigens.
CrisBio® uses pupae from the Trichoplusia ni, the natural host of the AcMNPV baculovirus vector used in the commercial vaccine production.

CrisBio®
CrisBio®

> than 1mg of purified recombinant protein per insect in average

CrisBio® manufacturing process

Insect rearing in disposable boxes

Insect rearing in disposable boxes

Pupae desilking (automated)

Pupae desilking (automated)

Clean pupae

Clean pupae

Pupae pick & place (automated)

Pupae pick & place (automated)

Automated pupae inoculation
Baculovirus generation Baculovirus generation

Automated pupae inoculation

Frozen pupae biomass

Frozen pupae biomass

Downstream

Downstream

Purified protein

Purified protein

GMP

RFID-tagged disposable trays

RFID-tagged disposable trays

1 of 3

Insect rearing in disposable boxes

Insect rearing in disposable boxes

Pupae desilking (automated)

Pupae desilking (automated)

Clean pupae

Clean pupae

Pupae pick & place (automated)

Pupae pick & place (automated)

RFID-tagged disposable trays

RFID-tagged disposable trays

Automated pupae inoculation

Automated pupae inoculation

Baculovirus generation Baculovirus generation

GMP

Frozen pupae biomass

Frozen pupae biomass

GMP

Downstream

Downstream

GMP

Purified protein

Purified protein

GMP

Publications on CrisBio®

Sep 16

Rotavirus A-specific single-domain antibodies produced in ba...

Learn more
Sep 16

Development of a low-cost, insect larvae-derived recombinant...

Learn more

TopBac®

TopBac®

TopBac® consists in a proprietary patented expression cassette composed by several genetic regulatory elements working in cascade. When incorporated into the genome of a baculovirus vector, TopBac® significantly improves the productivity and quality of recombinant proteins produced by host cells.

TopBac® is fully compatible with the most common baculovirus vector-based production technologies, consistently providing increase in production yields in insect cells significantly above current industry standards. TopBac® has also demonstrated its capacity to improve product quality by reducing foreign protein proteolysis. TopBac® has been tested for the production of a variety of proteins in insect cells and in combination with CrisBio®, significantly increasing productivities in both platforms.

Publications on TopBac®

Sep 16

Improved Production Efficiency of Virus-Like Particles by th...

Learn more
Sep 16

Significant Productivity Improvement of the Baculovirus Expr...

Learn more
Sep 16

Download Top-Bac® flyer

Learn more